Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Targeting Metastatic Hormone Sensitive Prostate Cancer: Chemohormonal Therapy and New Combinatorial Approaches.

Damodaran S, Lang JM, Jarrard DF.

J Urol. 2019 May;201(5):876-885. doi: 10.1097/JU.0000000000000117.

PMID:
30747897
2.

Clinical Outcomes of First-line Abiraterone Acetate or Enzalutamide for Metastatic Castration-resistant Prostate Cancer After Androgen Deprivation Therapy + Docetaxel or ADT Alone for Metastatic Hormone-sensitive Prostate Cancer.

Francini E, Yip S, Ahmed S, Li H, Ardolino L, Evan CP, Kaymakcalan M, Shaw GK, Kantoff PW, Taplin ME, Alimohamed NS, Joshua AM, Heng DYC, Sweeney CJ.

Clin Genitourin Cancer. 2018 Apr;16(2):130-134. doi: 10.1016/j.clgc.2017.12.012. Epub 2017 Dec 27.

3.

EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.

Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N; European Association of Urology.

Eur Urol. 2014 Feb;65(2):467-79. doi: 10.1016/j.eururo.2013.11.002. Epub 2013 Nov 12. Review.

PMID:
24321502
4.

[Patients with metastatic prostate cancer : Recommendations for primary hormonal or chemohormonal therapy].

Ohlmann CH.

Urologe A. 2017 Nov;56(11):1424-1429. doi: 10.1007/s00120-017-0517-y. Review. German.

PMID:
28983763
5.

The evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivation.

McNamara M, Sweeney C, Antonarakis ES, Armstrong AJ.

Prostate Cancer Prostatic Dis. 2018 Sep;21(3):306-318. doi: 10.1038/s41391-017-0014-9. Epub 2017 Dec 20. Review.

PMID:
29263421
6.

Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.

Crawford ED, Higano CS, Shore ND, Hussain M, Petrylak DP.

J Urol. 2015 Dec;194(6):1537-47. doi: 10.1016/j.juro.2015.06.106. Epub 2015 Jul 18. Review.

PMID:
26196735
7.

Taxane-based chemohormonal therapy for metastatic hormone-sensitive prostate cancer.

Sathianathen NJ, Philippou YA, Kuntz GM, Konety BR, Gupta S, Lamb AD, Dahm P.

Cochrane Database Syst Rev. 2018 Oct 15;10:CD012816. doi: 10.1002/14651858.CD012816.pub2.

PMID:
30320443
8.

Comparison of Abiraterone Acetate and Docetaxel with Androgen Deprivation Therapy in High-risk and Metastatic Hormone-naïve Prostate Cancer: A Systematic Review and Network Meta-analysis.

Wallis CJD, Klaassen Z, Bhindi B, Goldberg H, Chandrasekar T, Farrell AM, Boorjian SA, Kulkarni GS, Karnes RJ, Satkunasivam R.

Eur Urol. 2018 Jun;73(6):834-844. doi: 10.1016/j.eururo.2017.10.002. Epub 2017 Oct 14.

PMID:
29037513
9.

Intermittent androgen deprivation therapy in advanced prostate cancer.

Alva A, Hussain M.

Curr Treat Options Oncol. 2014 Mar;15(1):127-36. doi: 10.1007/s11864-013-0272-2. Review.

PMID:
24395278
10.

Taxane-based Combination Therapies for Metastatic Prostate Cancer.

Corn PG, Agarwal N, Araujo JC, Sonpavde G.

Eur Urol Focus. 2017 Dec 20. pii: S2405-4569(17)30265-1. doi: 10.1016/j.euf.2017.11.009. [Epub ahead of print] Review.

PMID:
29275145
11.

Emerging Therapies in Metastatic Prostate Cancer.

Sonnenburg DW, Morgans AK.

Curr Oncol Rep. 2018 Apr 11;20(6):46. doi: 10.1007/s11912-018-0692-z. Review.

PMID:
29644451
12.

Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.

Lavaud P, Gravis G, Foulon S, Joly F, Oudard S, Priou F, Latorzeff I, Mourey L, Soulié M, Delva R, Krakowski I, Laguerre B, Théodore C, Ferrero JM, Beuzeboc P, Habibian M, Rolland F, Deplanque G, Pouessel D, Zanetta S, Berdah JF, Dauba J, Baciuchka M, Platini C, Linassier C, Tubiana-Mathieu N, Machiels JP, Kouri CE, Ravaud A, Suc E, Eymard JC, Hasbini A, Bousquet G, Culine S, Boher JM, Tergemina-Clain G, Legoupil C, Fizazi K.

Eur Urol. 2018 May;73(5):696-703. doi: 10.1016/j.eururo.2017.09.022. Epub 2017 Oct 23.

PMID:
29074061
13.

Current status of primary pharmacotherapy and future perspectives toward upfront therapy for metastatic hormone-sensitive prostate cancer.

Shiota M, Eto M.

Int J Urol. 2016 May;23(5):360-9. doi: 10.1111/iju.13091. Epub 2016 Apr 8. Review.

14.

Contemporary Management of the Newly Diagnosed Prostate Cancer Patient with Metastatic Disease at Presentation.

Xu L, Pachynski RK.

Curr Urol Rep. 2018 Aug 13;19(10):79. doi: 10.1007/s11934-018-0835-7. Review.

PMID:
30105573
15.

[Drug therapy of hormone-sensitive metastatic prostate cancer : Consensus paper of the AKO/AUO].

Ohlmann CH, Gschwend J, Miller K.

Urologe A. 2016 Sep;55(9):1164-72. doi: 10.1007/s00120-016-0178-2. German.

PMID:
27431813
16.

Docetaxel in hormone-sensitive advanced prostate cancer; GENESIS-SEFH evaluation reporta.

García de Paredes Esteban JC, Alegre Del Rey EJ, Asensi Díez R.

Farm Hosp. 2017 Jul 1;41(4):550-558. doi: 10.7399/fh.2017.41.4.10742.

18.

Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial.

Chi KN, Protheroe A, Rodríguez-Antolín A, Facchini G, Suttman H, Matsubara N, Ye Z, Keam B, Damião R, Li T, McQuarrie K, Jia B, De Porre P, Martin J, Todd MB, Fizazi K.

Lancet Oncol. 2018 Feb;19(2):194-206. doi: 10.1016/S1470-2045(17)30911-7. Epub 2018 Jan 8.

PMID:
29326030
19.

Chemohormonal therapy for metastatic hormone-sensitive prostate cancer: An Asian perspective.

Teoh JY, Ng CF, Poon DM.

Asia Pac J Clin Oncol. 2018 Nov;14 Suppl 5:5-8. doi: 10.1111/ajco.13060. Review.

PMID:
30489034
20.

Addition of Docetaxel to Androgen Deprivation Therapy for Patients with Hormone-sensitive Metastatic Prostate Cancer: A Systematic Review and Meta-analysis.

Tucci M, Bertaglia V, Vignani F, Buttigliero C, Fiori C, Porpiglia F, Scagliotti GV, Di Maio M.

Eur Urol. 2016 Apr;69(4):563-573. doi: 10.1016/j.eururo.2015.09.013. Epub 2015 Sep 28. Review.

Supplemental Content

Support Center